Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy (REMOD-REVERT)

Main Inclusion Criteria: Provision of signed informed consent prior to any study-specific procedures. Male or female of non-childbearing potential patients age ≥40 and <85 years. Documented diagnosis of symptomatic heart failure (NYHA class II-IV) at enrollment, and a medical history of typical symptoms/signs of heart failure ≥6 weeks before enrollment with at least intermittent need for diuretic treatment. Ejection fraction ≥ 45% (determined by echocardiography at site laboratory) Increased intraventricular wall thickness (≥11 mm for female and ≥12 mm for male patients by echocardiography at site laboratory) NT-proBNP > 300 pg/ml (sinus rhythm); >900 pg/ml (atrial fibrillation at time of screening/inclusion or documented with the last 6 months) BMI between 22 kg/m² and 45 kg/m². Main Exclusion Criteria: Hemoglobin A1C (A1C) ≥10.5% eGFR <35 mL/min/1.73m² Systolic blood pressure (BP) <90 mmHg on 2 consecutive measurements at 5-minute intervals, at Screening. Systolic BP≥180 mmHg on 2 consecutive measurements at 5-minute intervals, at Screening. Planned coronary revascularization, ablation of atrial flutter/fibrillation and valve repair/replacement. Stroke or transient ischemic attack (TIA) within 12 weeks prior to enrolment.